November/December 2010

Please make all necessary changes on your copies of the National Drug Schedules and applicable Federal Legislation. Updated copies of these documents are available on the NAPRA website at www.napra.ca

**NAPRA National Drug Schedules Notice Board**

**Breastlight is Not Authorized for Use as a Screening Device for the Detection of Breast Cancer**
November 16, 2010

Health Canada is informing Canadians that PWB Health Ltd. (the “Company”) is recalling its Breastlight product which is currently available on the Canadian market. PWB Health Ltd. is requesting that pharmacies and other distributors immediately stop sale of this product.

**Schedule Status of naproxen sodium 220 mg per tablet**
November 11, 2010

The Initial Recommendation made by the National Drug Scheduling Advisory Committee (NDSAC) on September 12, 2010 for the scheduling of:

- Naproxen sodium 220 mg per tablet (when sold in products labeled with a recommended maximum daily dose of 440 mg, and in package sizes of up to 6,600 mg) to be **Unscheduled**

was finalized effective November 10, 2010. Final approval of the Initial Recommendation was made by NAPRA’s Executive Committee, in consideration of comments received during the 30-day review period. The National Drug Schedules will be revised accordingly.

At the request of NAPRA’s Executive Committee, the National Drug Scheduling Advisory Committee will conduct a reassessment of the request for:

- Unscheduled status of Naproxen sodium 220 mg per tablet (when sold in products labeled with a recommended maximum daily dose of 440 mg, and in package sizes exceeding 6,600 mg)

at the meeting scheduled March 6-7, 2011.

November/December 2010

For a complete listing of the most recent changes to the National Drug Schedules, visit the Drug Schedules Notice Board at www.napra.ca
**Notices of Proposed Schedule F Amendments**

This is to inform you that Health Canada has recommended the following medicinal ingredients be added to Schedule F to the *Food and Drug Regulations*. Pursuant to the NAPRA Policy for "Schedule F Recommended" Drugs, the following noted medicinal ingredients have been added to the National Drug Schedules - Schedule I, effective August 25, 2010:

**Medicinal Ingredient:**
Tocilizumab  
**Date NOC issued:**  
April 30, 2010

**Medicinal Ingredient:**
Canakinumab  
**Date NOC issued:**  
February 26, 2010

**Medicinal Ingredient:**
Prasugrel and its salts  
**Date NOC issued**  
July 27, 2010

**Medicinal Ingredient:**
Sapropterin and its salts  
**Date NOC issued:**  
April 30, 2010